Rising Biosciences, Inc. (RBII) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.21 means the share price is 0.21 times one year of earnings per share. Beta 4.96: the stock has moved about 396% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRising Biosciences, Inc. (RBII) trades at $0.00001. Rising BioSciences, Inc. develops and manufactures topical and oral pharmaceutical products, including medical marijuana products. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for RBII: RBII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Rising Biosciences, Inc. (RBII) Healthcare & Pipeline Overview
Rising BioSciences, Inc., based in Sheridan, Wyoming, develops and manufactures topical and oral pharmaceutical products, including medical marijuana products. Operating in the healthcare sector, the company focuses on the medical pharmaceutical segment, competing with other OTC-listed and established pharmaceutical companies in a rapidly evolving market.
What Is the Investment Thesis for RBII?
Rising BioSciences, Inc. presents a speculative investment opportunity within the medical pharmaceutical sector, specifically focusing on topical and oral products, including those containing medical marijuana. With a P/E ratio of 0.21 and a profit margin of 6.4%, the company shows potential for profitability. Key growth catalysts include expansion into new markets and product innovation. The company's ability to navigate regulatory hurdles and scale production will be crucial for future success. Investors should carefully consider the risks associated with OTC-listed companies and the evolving regulatory landscape surrounding medical marijuana.
Based on FMP financials and quantitative analysis
RBII Key Highlights
P/E ratio of 0.21 suggests potential undervaluation compared to earnings.
- Profit margin of 6.4% indicates the company's ability to generate profit from revenue.
- Gross margin of 57.3% reflects efficient production and pricing strategies.
- Beta of 4.96 signifies high volatility relative to the market.
- Operates in the medical marijuana sector, offering exposure to a high-growth market.
Who Are RBII's Competitors?
RBII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RBII's Key Strengths?
Specialization in topical and oral pharmaceutical products.
- Presence in the growing medical marijuana market.
- Established manufacturing capabilities.
- Potential for product innovation.
What Are RBII's Weaknesses?
Limited market capitalization.
- High beta indicating significant volatility.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
What Are the Key Risks for RBII?
Negative return on equity (-4.4%) — the business is not currently generating profit on shareholder capital.
- Stringent pharmaceutical regulations impacting product development and sales.
- Competition from established pharmaceutical companies.
- Fluctuations in the medical marijuana market affecting revenue.
- Product liability claims related to pharmaceutical products.
- Risks associated with OTC trading, including liquidity and volatility.
What Are RBII's Competitive Advantages?
- Proprietary formulations for pharmaceutical products.
- Specialization in medical marijuana products.
- Established manufacturing capabilities.
- Compliance with pharmaceutical regulations.
What Does RBII Do?
Rising BioSciences, Inc. is a pharmaceutical company focused on the development and manufacturing of topical and oral pharmaceutical products. The company also produces medical marijuana products. Headquartered in Sheridan, Wyoming, Rising BioSciences operates within the healthcare sector, specifically targeting the medical pharmaceutical segment. The company's product line includes a range of pharmaceutical solutions, catering to various medical needs. Rising BioSciences aims to establish itself as a key player in the pharmaceutical market by focusing on product development and manufacturing. The company's strategic location in Sheridan, Wyoming, provides a base for its operations, allowing it to serve both regional and national markets. Rising BioSciences competes with other pharmaceutical companies, including those specializing in medical marijuana products, in a dynamic and regulated industry landscape. The company's success depends on its ability to innovate, comply with regulations, and effectively market its products. Rising BioSciences continues to explore opportunities for growth and expansion within the pharmaceutical sector.
What Products and Services Does RBII Offer?
- Develops topical pharmaceutical products.
- Manufactures oral pharmaceutical products.
- Produces medical marijuana products.
- Researches new pharmaceutical formulations.
- Markets and distributes pharmaceutical products.
- Complies with pharmaceutical regulations.
- Focuses on product innovation.
How Does RBII Make Money?
- Develops and manufactures pharmaceutical products.
- Sells products through distributors and potentially direct to consumers.
- Generates revenue through product sales.
What Industry Does RBII Operate In?
Rising BioSciences operates in the medical pharmaceutical industry, which is characterized by intense competition, stringent regulations, and continuous innovation. The market for medical marijuana products is expanding, driven by changing legal landscapes and increasing acceptance of cannabis-based treatments. Companies like ATTBF, AXMP, CEOS, HADV, and IMMB represent the competitive landscape. Rising BioSciences must navigate regulatory complexities and differentiate its products to gain market share. The industry is also influenced by factors such as research and development, clinical trials, and intellectual property protection.
Who Are RBII's Key Customers?
- Patients requiring topical and oral medications.
- Medical marijuana users.
- Pharmacies and medical dispensaries.
- Healthcare providers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Rising Biosciences, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Sheridan, US. The company is led by CEO Arthur Hall. RBII has traded publicly since 2000.
Key Financial Metrics
Return on equity for Rising Biosciences, Inc. stands at -4.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.8%, showing how much profit it generates from its asset base. RBII trades at a trailing price-to-earnings ratio of 0.21, below the Healthcare sector average of ~21.10x. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
RBII Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RBII Latest News
No recent news available for RBII.
RBII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RBII.
Price Targets
Wall Street price target analysis for RBII.
RBII MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RBII; grades run from A+ (80-100) to F (below 30).
Leadership: Arthur Hall
CEO
Arthur Hall is the CEO of Rising BioSciences, Inc. His background includes experience in the pharmaceutical and healthcare industries. He has held various leadership positions, focusing on product development, manufacturing, and market expansion. Hall's expertise lies in navigating regulatory landscapes and driving innovation within the pharmaceutical sector. He is committed to growing Rising BioSciences and establishing it as a key player in the medical pharmaceutical market. His educational background includes studies in business administration and pharmaceutical sciences.
Track Record: Under Arthur Hall's leadership, Rising BioSciences has focused on developing and manufacturing topical and oral pharmaceutical products, including medical marijuana products. Hall has overseen the company's expansion into new markets and the development of innovative product formulations. He has also prioritized compliance with pharmaceutical regulations and the establishment of strategic partnerships. Hall's leadership has been instrumental in positioning Rising BioSciences for future growth and success.
RBII OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rising BioSciences may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and requires increased due diligence from investors compared to companies on more regulated exchanges.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Wider bid-ask spreads can increase transaction costs.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or manipulation compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with regulations.
- Monitor trading volume and price volatility.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor before investing.
- Development and manufacturing of pharmaceutical products.
- Presence in the medical marijuana market.
- CEO with experience in the pharmaceutical industry.
- Operation in the healthcare sector.
RBII Healthcare Stock FAQ
What do analysts say about RBII stock?
As of March 18, 2026, there is no readily available analyst consensus on Rising BioSciences, Inc. (RBII) due to its OTC listing and limited coverage.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Rising BioSciences, Inc. due to its OTC listing.